Please assess the completion status of the following clinical trial:

Trial Title: The Efficacy of the Tailored Therapy Based on Antimicrobial Susceptibility for 2nd Eradication of H. Pylori

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* The patients who proved a failure of 1st eradication of H. pylori with Proton pump inhibitor based triple therapy (PPI bid + amoxacillin 1g b.i.d + Clarithromycin 500 mg b.i.d) or sequential therapy (initial 5-day therapy with a combination of PPI b.i.d and amoxicillin 1g b.i.d, followed by 5 days of PPI b.i.d., clarithromycin 500mg b.i.d., and metronidazole 500mg t.i.d) following three methods~  1. positive rapid urease test (CLOtest)~ 2. histologic evidence of H. pylori by modified Giemsa staining~ 3. positive 13C-Urea breath test~* Male and female Korean Adult (Aged ≥ 18 years)~Exclusion Criteria:~* Patients who received two or more eradication therapy for H. pylori infection~* H. pylori eradication failure because of poor compliance~* the administration of antibiotics or the consumption of bismuth salts within 4 weeks or the administration of a proton pump inhibitor (PPI) within 2 weeks~* Advanced gastric cancer or other malignancy~* Abnormal liver function or liver cirrhosis~* Abnormal renal function or chronic kidney disease~* Other severe concurrent diseases~* Previous allergic reactions to the study drugs~* Pregnant or lactating women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- 14 day bismuth based quadruple therapy (PBMT) group (Type: EXPERIMENTAL): Proton pump inhibitor (PPI) regular dose b.i.d., tripotassium dicitrate bismuthate 300 mg q.i.d. (three tablets at 30 min before meals and one tablet at 2 hours after dinner), metronidazole 500 mg t.i.d., and tetracycline 500 mg q.i.d
- 14 day Moxifloxacin containing triple therapy (MEA) group (Type: EXPERIMENTAL): PPI regular dose b.i.d., moxifloxacin 400 mg q.d., and amoxicillin 1g b.i.d.
- 14 day tailored therapy group (Type: ACTIVE_COMPARATOR): based on H. pylori culture and antimicrobial sensitivity, select the 2nd rescue regimen between 14 days of bismuth-based quadruple therapy or 14 days moxifloxacin-containing triple therapy according to antibiotics susceptibility.

Based on this trial design, predict the completion outcome and termination type (if applicable).